BRIDGEBIO PHARMA, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of March 9, 2020 2.50% Convertible Senior Notes due 2027Indenture • March 10th, 2020 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • New York
INDENTURE dated as of March 9, 2020 between BRIDGEBIO PHARMA, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, as trustee (the “Trustee,” as more fully set forth in Section 1.01).
March [__], 2020 From: [Dealer] To: BridgeBio Pharma, Inc. Palo Alto, CA 94301 Attention: Chief Financial Officer Telephone: 650-391-9740 Re: [Base][Additional] Call Option TransactionCall Option Transaction • March 10th, 2020 • BridgeBio Pharma, Inc. • Pharmaceutical preparations
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [_________] (“Dealer”) and BridgeBio Pharma, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Counterparty and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto.
